Baxter International Inc. BAX is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its third quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by of 44 cents and increased from 41 cents in the year-ago quarter.
Revenues: Baxter posted sales of $2,558 million, beating the Zacks Consensus Estimate for revenues of $2,545 million. At constant currency (cc), revenues increased 4% on a year-over-year basis.
Key Stats: Hospital products sales increased 3% at cc, while renal products went up 6% from the year-ago quarter.
Major Factors: Hospital Products sales were driven by solid demand for IV solutions, nutritional therapies, pharmacy injectables and IV access administration sets. Renal products sales were driven by peritoneal dialysis products as well as increased demand globally for continuous renal replacement therapies.
BAXTER INTL Price
BAXTER INTL Price | BAXTER INTL Quote
Stock Price: Following the earnings release, share price rose 2.48% in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAXTER INTL (BAX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research